Connor, Clark & Lunn Investment Management Ltd. Viking Therapeutics, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$26 Billion
Q2 2025

A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 447,217 shares of VKTX stock, worth $14.8 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

447,217

Previous 597,515 25.15%

Holding current value

$14.8 Million

Previous $14.4 Million 17.87%

% of portfolio

0.05%

Previous 0.07%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 07, 2025	SELL	$19.98 - $29.49 $3 Million - $4.43 Million	-150,298 Reduced 25.15%	447,217 $11.9 Million
Q1 2025 May 12, 2025	BUY	$24.15 - $42.89 $5.37 Million - $9.53 Million	222,293 Added 59.24%	597,515 $14.4 Million
Q4 2024 Feb 10, 2025	BUY	$38.28 - $78.03 $8.3 Million - $16.9 Million	216,873 Added 136.96%	375,222 $15.1 Million
Q3 2024 Nov 08, 2024	BUY	$49.84 - $70.47 $5.41 Million - $7.65 Million	108,581 Added 218.17%	158,349 $10 Million
Q2 2024 Aug 09, 2024	BUY	$47.39 - $80.2 $2.36 Million - $3.99 Million	49,768 New	49,768 $2.64 Million
Q3 2023 Nov 13, 2023	SELL	$10.92 - $16.0 $1.32 Million - $1.94 Million	-121,051 Reduced 61.32%	76,360 $845,000
Q2 2023 Aug 10, 2023	BUY	$14.84 - $24.79 $1.59 Million - $2.65 Million	106,985 Added 118.31%	197,411 $3.2 Million
Q1 2023 May 09, 2023	BUY	$8.08 - $17.33 $17,614 - $37,779	2,180 Added 2.47%	90,426 $1.51 Million
Q4 2022 Feb 10, 2023	SELL	$2.72 - $9.4 $466,863 - $1.61 Million	-171,641 Reduced 66.04%	88,246 $829,000
Q3 2022 Nov 10, 2022	BUY	$2.55 - $3.89 $94,413 - $144,027	37,025 Added 16.61%	259,887 $707,000
Q2 2022 Aug 05, 2022	BUY	$2.11 - $3.15 $219,769 - $328,091	104,156 Added 87.74%	222,862 $644,000
Q1 2022 May 12, 2022	BUY	$3.0 - $4.88 $238,521 - $387,994	79,507 Added 202.83%	118,706 $356,000
Q4 2021 Feb 10, 2022	BUY	$4.6 - $6.72 $70,145 - $102,473	15,249 Added 63.67%	39,199 $180,000
Q3 2021 Nov 12, 2021	BUY	$5.58 - $7.04 $55,459 - $69,970	9,939 Added 70.94%	23,950 $150,000
Q2 2021 Aug 12, 2021	BUY	$5.19 - $6.73 $72,717 - $94,294	14,011 New	14,011 $84,000

Others Institutions Holding VKTX

# of Institutions

456

Shares Held

67.9M

Call Options Held

7.72M

Put Options Held

3.31M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $2.54B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account

Connor, Clark & Lunn Investment Management Ltd. Viking Therapeutics, Inc. Transaction History